(Reuters) - The Food and Drug Administration reinspected the St. Paul, Minnesota, facility between Nov. 9 and Dec. 7. The facility had been owned by Guidant, which Boston Scientific acquired last year. The FDA had issued Guidant a warning letter about the deficiencies on Dec. 22, 2005.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment